Scholar Rock Secures FDA Approval for Groundbreaking SMA Therapy

In a significant advancement for patients with spinal muscular atrophy (SMA), Scholar Rock announced on Friday that its drug Isembyld has received FDA approval. This marks the first therapy specifically designed to combat muscle loss associated with the rare neurological disorder, offering new hope for enhanced mobility and independence.

The FDA's green light allows Isembyld to be administered to both adults and children aged two and older who are already undergoing treatment targeting the SMN2 gene, crucial for motor neuron function. A recent late-stage clinical trial highlighted the drug's effectiveness; young patients receiving Isembyld alongside an SMN2-targeting therapy showed notable improvements in motor skills after one year, contrasting with a decline observed in the placebo group.

David Hallal, CEO of Scholar Rock, expressed his enthusiasm for the approval, stating, “Today’s FDA approval of Isembyld marks a defining moment for the SMA community. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough.”

Source: www.statnews.com